2022-07-012023-06-302023-06-30false12639458GEORGE MEDICINES UK LIMITED2024-02-12iso4217:GBPxbrli:pure126394582022-07-01126394582023-06-30126394582022-07-012023-06-30126394582021-07-01126394582022-06-30126394582021-07-012022-06-3012639458bus:SmallEntities2022-07-012023-06-3012639458bus:AuditExempt-NoAccountantsReport2022-07-012023-06-3012639458bus:AbridgedAccounts2022-07-012023-06-3012639458bus:PrivateLimitedCompanyLtd2022-07-012023-06-3012639458core:WithinOneYear2023-06-3012639458core:AfterOneYear2023-06-3012639458core:WithinOneYear2022-06-3012639458core:AfterOneYear2022-06-3012639458core:ShareCapital2023-06-3012639458core:SharePremium2023-06-3012639458core:RevaluationReserve2023-06-3012639458core:OtherReservesSubtotal2023-06-3012639458core:RetainedEarningsAccumulatedLosses2023-06-3012639458core:ShareCapital2022-06-3012639458core:SharePremium2022-06-3012639458core:RevaluationReserve2022-06-3012639458core:OtherReservesSubtotal2022-06-3012639458core:RetainedEarningsAccumulatedLosses2022-06-3012639458core:LandBuildings2023-06-3012639458core:PlantMachinery2023-06-3012639458core:Vehicles2023-06-3012639458core:FurnitureFittings2023-06-3012639458core:OfficeEquipment2023-06-3012639458core:NetGoodwill2023-06-3012639458core:IntangibleAssetsOtherThanGoodwill2023-06-3012639458core:ListedExchangeTraded2023-06-3012639458core:UnlistedNon-exchangeTraded2023-06-3012639458core:LandBuildings2022-06-3012639458core:PlantMachinery2022-06-3012639458core:Vehicles2022-06-3012639458core:FurnitureFittings2022-06-3012639458core:OfficeEquipment2022-06-3012639458core:NetGoodwill2022-06-3012639458core:IntangibleAssetsOtherThanGoodwill2022-06-3012639458core:ListedExchangeTraded2022-06-3012639458core:UnlistedNon-exchangeTraded2022-06-3012639458core:LandBuildings2022-07-012023-06-3012639458core:PlantMachinery2022-07-012023-06-3012639458core:Vehicles2022-07-012023-06-3012639458core:FurnitureFittings2022-07-012023-06-3012639458core:OfficeEquipment2022-07-012023-06-3012639458core:NetGoodwill2022-07-012023-06-3012639458core:IntangibleAssetsOtherThanGoodwill2022-07-012023-06-3012639458core:ListedExchangeTraded2022-07-012023-06-3012639458core:UnlistedNon-exchangeTraded2022-07-012023-06-3012639458core:MoreThanFiveYears2022-07-012023-06-3012639458core:Non-currentFinancialInstruments2023-06-3012639458core:Non-currentFinancialInstruments2022-06-3012639458dpl:CostSales2022-07-012023-06-3012639458dpl:DistributionCosts2022-07-012023-06-3012639458core:LandBuildings2022-07-012023-06-3012639458core:PlantMachinery2022-07-012023-06-3012639458core:Vehicles2022-07-012023-06-3012639458core:FurnitureFittings2022-07-012023-06-3012639458core:OfficeEquipment2022-07-012023-06-3012639458dpl:AdministrativeExpenses2022-07-012023-06-3012639458core:NetGoodwill2022-07-012023-06-3012639458core:IntangibleAssetsOtherThanGoodwill2022-07-012023-06-3012639458dpl:GroupUndertakings2022-07-012023-06-3012639458dpl:ParticipatingInterests2022-07-012023-06-3012639458dpl:GroupUndertakingscore:ListedExchangeTraded2022-07-012023-06-3012639458core:ListedExchangeTraded2022-07-012023-06-3012639458dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-07-012023-06-3012639458core:UnlistedNon-exchangeTraded2022-07-012023-06-3012639458dpl:CostSales2021-07-012022-06-3012639458dpl:DistributionCosts2021-07-012022-06-3012639458core:LandBuildings2021-07-012022-06-3012639458core:PlantMachinery2021-07-012022-06-3012639458core:Vehicles2021-07-012022-06-3012639458core:FurnitureFittings2021-07-012022-06-3012639458core:OfficeEquipment2021-07-012022-06-3012639458dpl:AdministrativeExpenses2021-07-012022-06-3012639458core:NetGoodwill2021-07-012022-06-3012639458core:IntangibleAssetsOtherThanGoodwill2021-07-012022-06-3012639458dpl:GroupUndertakings2021-07-012022-06-3012639458dpl:ParticipatingInterests2021-07-012022-06-3012639458dpl:GroupUndertakingscore:ListedExchangeTraded2021-07-012022-06-3012639458core:ListedExchangeTraded2021-07-012022-06-3012639458dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-07-012022-06-3012639458core:UnlistedNon-exchangeTraded2021-07-012022-06-3012639458core:NetGoodwill2023-06-3012639458core:IntangibleAssetsOtherThanGoodwill2023-06-3012639458core:LandBuildings2023-06-3012639458core:PlantMachinery2023-06-3012639458core:Vehicles2023-06-3012639458core:FurnitureFittings2023-06-3012639458core:OfficeEquipment2023-06-3012639458core:AfterOneYear2023-06-3012639458core:WithinOneYear2023-06-3012639458core:ListedExchangeTraded2023-06-3012639458core:UnlistedNon-exchangeTraded2023-06-3012639458core:ShareCapital2023-06-3012639458core:SharePremium2023-06-3012639458core:RevaluationReserve2023-06-3012639458core:OtherReservesSubtotal2023-06-3012639458core:RetainedEarningsAccumulatedLosses2023-06-3012639458core:NetGoodwill2022-06-3012639458core:IntangibleAssetsOtherThanGoodwill2022-06-3012639458core:LandBuildings2022-06-3012639458core:PlantMachinery2022-06-3012639458core:Vehicles2022-06-3012639458core:FurnitureFittings2022-06-3012639458core:OfficeEquipment2022-06-3012639458core:AfterOneYear2022-06-3012639458core:WithinOneYear2022-06-3012639458core:ListedExchangeTraded2022-06-3012639458core:UnlistedNon-exchangeTraded2022-06-3012639458core:ShareCapital2022-06-3012639458core:SharePremium2022-06-3012639458core:RevaluationReserve2022-06-3012639458core:OtherReservesSubtotal2022-06-3012639458core:RetainedEarningsAccumulatedLosses2022-06-3012639458core:NetGoodwill2021-07-0112639458core:IntangibleAssetsOtherThanGoodwill2021-07-0112639458core:LandBuildings2021-07-0112639458core:PlantMachinery2021-07-0112639458core:Vehicles2021-07-0112639458core:FurnitureFittings2021-07-0112639458core:OfficeEquipment2021-07-0112639458core:AfterOneYear2021-07-0112639458core:WithinOneYear2021-07-0112639458core:ListedExchangeTraded2021-07-0112639458core:UnlistedNon-exchangeTraded2021-07-0112639458core:ShareCapital2021-07-0112639458core:SharePremium2021-07-0112639458core:RevaluationReserve2021-07-0112639458core:OtherReservesSubtotal2021-07-0112639458core:RetainedEarningsAccumulatedLosses2021-07-0112639458core:AfterOneYear2022-07-012023-06-3012639458core:WithinOneYear2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:CostValuation2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-07-012023-06-3012639458core:Non-currentFinancialInstrumentscore:CostValuation2023-06-3012639458core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-3012639458core:Non-currentFinancialInstrumentscore:CostValuation2022-06-3012639458core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-06-3012639458core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-06-3012639458bus:Director12022-07-012023-06-3012639458bus:Director22022-07-012023-06-3012639458bus:Director32022-07-012023-06-30

GEORGE MEDICINES UK LIMITED

Registered Number
12639458
(England and Wales)

Unaudited Financial Statements for the Year ended
30 June 2023

GEORGE MEDICINES UK LIMITED
Company Information
for the year from 1 July 2022 to 30 June 2023

Directors

FEATHERSTON, Scott
LEAVENWORTH-BAKALI, Mustapha
WAHLQVIST, Ingmar Wei Tzu, Dr

Registered Address

124 City Road
London
EC1V 2NX

Registered Number

12639458 (England and Wales)
GEORGE MEDICINES UK LIMITED
Balance Sheet as at
30 June 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets6-468
-468
Current assets
Debtors768,882216,561
Cash at bank and on hand121,026366,441
889,908583,002
Creditors amounts falling due within one year399,549343,101
Net current assets (liabilities)490,359239,901
Total assets less current liabilities490,359240,369
Net assets490,359240,369
Capital and reserves
Called up share capital100100
Profit and loss account490,259240,269
Shareholders' funds490,359240,369
The financial statements were approved and authorised for issue by the Board of Directors on 12 February 2024, and are signed on its behalf by:
FEATHERSTON, Scott
Director
Registered Company No. 12639458
GEORGE MEDICINES UK LIMITED
Notes to the Financial Statements
for the year ended 30 June 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
George Medicines UK Limited is engaged in Medical Research activities
4.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Revenue recognition policy
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Taxation policy
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Foreign currency translation and operations policy
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
Going concern
On the basis of their assessment of the company’s financial position, banking arrangements and current year forecast, and of the enquiries made of the directors of the company’s parent, the company’s directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual report and accounts.
5.Employee information

20232022
Average number of employees during the year44
6.Property, plant and equipment

Total

£
Cost or valuation
At 01 July 22935
Depreciation and impairment
At 01 July 22468
Charge for year467
Net book value
At 30 June 23-
At 30 June 22468